Dhaval Patel1, Sudheer Kumar Gara1, Ryan J Ellis2, Myriem Boufraqech1, Naris Nilubol1, Corina Millo3, Constantine A Stratakis4, Electron Kebebew5. 1. Endocrine Oncology Branch, Clinical Research Center, National Cancer Institute, NIH, Building 10-CRC, Room 3-5840, Bethesda, MD, 20892, USA. 2. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA. 3. PET Department, Clinical Center, NIH, Bethesda, MD, 20892, USA. 4. Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, 20892, USA. 5. Endocrine Oncology Branch, Clinical Research Center, National Cancer Institute, NIH, Building 10-CRC, Room 3-5840, Bethesda, MD, 20892, USA. kebebewe@mail.nih.gov.
Abstract
BACKGROUND: Patients with Cushing's Syndrome (CS) and Conn's Syndrome with bilateral adrenal masses pose a dilemma. Uptake of 18F-FDG by hyperfunctioning adrenal glands has not been previously reported and may help lateralize. The aim was to determine if 18F-FDG PET/CT scan could identify hyperfunctioning adrenal masses and determine a biological basis for uptake. METHODS: Patients with nonfunctional adenomas (n = 9), CS (n = 11), and Conn's syndrome (n = 4) underwent an 18F-FDG PET/CT scan with a volume of interest circumscribing each mass to obtain a maximal standardized uptake value (SUVmax). Thirty-two adrenal masses were analyzed. Genome-wide expression data from an independent cohort were analyzed in nonfunctioning adenomas (n = 20), Conn's syndrome (n = 29), and CS (n = 24) focusing on GLUT genes. For genes differentially expressed, immunohistochemistry was performed on tissue samples. RESULTS: Cortisol-secreting masses (n = 16) had a higher average SUVmax of 5.9 compared to nonfunctioning masses (n = 11, average SUVmax 4.2) and aldosterone-hypersecreting masses (n = 5, average SUVmax 3.2) (p = 0.007). SUVmax cut-off of 5.33 had 50.0% sensitivity and 81.8% specificity in localizing a cortisol-secreting mass. GLUT3 expression was 2.19-fold higher in patients with CS compared to patients with nonfunctioning adenomas (p = 0.003) and 2.16-fold higher in patients with CS compared to Conn's syndrome (p = 0.006). GLUT3 immunohistochemistry showed 2.2-fold higher staining in CS tumor samples compared to nonfunctioning adenomas. CONCLUSIONS: Differential 18F-FDG PET/CT uptake was observed in patients with nonfunctioning, aldosterone-hypersecreting, and cortisol-secreting masses. GLUT3 overexpression in cortisol-secreting tumor likely accounts for the differential uptake. Future larger cohort studies will need to be conducted to determine if 18F-FDG PET/CT uptake can lateralize cortisol-secreting adrenal masses in patients with bilateral adrenal masses.
BACKGROUND:Patients with Cushing's Syndrome (CS) and Conn's Syndrome with bilateral adrenal masses pose a dilemma. Uptake of 18F-FDG by hyperfunctioning adrenal glands has not been previously reported and may help lateralize. The aim was to determine if 18F-FDG PET/CT scan could identify hyperfunctioning adrenal masses and determine a biological basis for uptake. METHODS:Patients with nonfunctional adenomas (n = 9), CS (n = 11), and Conn's syndrome (n = 4) underwent an 18F-FDG PET/CT scan with a volume of interest circumscribing each mass to obtain a maximal standardized uptake value (SUVmax). Thirty-two adrenal masses were analyzed. Genome-wide expression data from an independent cohort were analyzed in nonfunctioning adenomas (n = 20), Conn's syndrome (n = 29), and CS (n = 24) focusing on GLUT genes. For genes differentially expressed, immunohistochemistry was performed on tissue samples. RESULTS:Cortisol-secreting masses (n = 16) had a higher average SUVmax of 5.9 compared to nonfunctioning masses (n = 11, average SUVmax 4.2) and aldosterone-hypersecreting masses (n = 5, average SUVmax 3.2) (p = 0.007). SUVmax cut-off of 5.33 had 50.0% sensitivity and 81.8% specificity in localizing a cortisol-secreting mass. GLUT3 expression was 2.19-fold higher in patients with CS compared to patients with nonfunctioning adenomas (p = 0.003) and 2.16-fold higher in patients with CS compared to Conn's syndrome (p = 0.006). GLUT3 immunohistochemistry showed 2.2-fold higher staining in CS tumor samples compared to nonfunctioning adenomas. CONCLUSIONS: Differential 18F-FDG PET/CT uptake was observed in patients with nonfunctioning, aldosterone-hypersecreting, and cortisol-secreting masses. GLUT3 overexpression in cortisol-secreting tumor likely accounts for the differential uptake. Future larger cohort studies will need to be conducted to determine if 18F-FDG PET/CT uptake can lateralize cortisol-secreting adrenal masses in patients with bilateral adrenal masses.
Authors: N Charnley; R Airley; D Du Plessis; C West; C Brock; C Barnett; J Matthews; K Symonds; M Bottomly; R Swindell; P Price Journal: Oncol Rep Date: 2008-09 Impact factor: 3.906
Authors: William F Young; Hendrick du Plessis; Geoffrey B Thompson; Clive S Grant; David R Farley; Melanie L Richards; Dana Erickson; Adrian Vella; Anthony W Stanson; J Aidan Carney; Charles F Abboud; Paul C Carpenter Journal: World J Surg Date: 2008-05 Impact factor: 3.352
Authors: Gustavo G Fernandez-Ranvier; Julie Weng; Ru-Fang Yeh; Elham Khanafshar; Insoo Suh; Christopher Barker; Quan Yang Duh; Orlo H Clark; Electron Kebebew Journal: Arch Surg Date: 2008-09
Authors: K C Yu; H R Alexander; H A Ziessman; J A Norton; J L Doppman; J F Buell; L K Nieman; G B Cutler; G P Chrousos; D L Fraker Journal: Surgery Date: 1995-12 Impact factor: 3.982